Publications by authors named "Yuanbin Chen"

Article Synopsis
  • * Researchers found that using a glutamine antagonist called DON reduced bladder cancer cell growth and inhibited tumor growth in mice with a modified drug (JHU083) to reduce side effects.
  • * However, prolonged treatment altered T-cell immune response, increasing PD-L1 expression in cancer cells; combining JHU083 with gefitinib helped counteract this and improved treatment effectiveness.
View Article and Find Full Text PDF
Article Synopsis
  • Asthma is a long-term inflammatory condition that causes changes in the airways, and researchers are investigating how epithelial-mesenchymal transition (EMT) contributes to these changes in asthma patients, particularly focusing on the effects of flavonoids like Luteolin (Lut).
  • The study aims to determine whether Lut can inhibit airway remodeling in asthma and explore the role of β-catenin in this process through both laboratory (cell and animal) experiments.
  • Various methods, including cell migration assays, gene expression analysis, and the evaluation of inflammatory cells in mice, were used to assess Lut’s effects on EMT and to understand its regulatory influence on β-catenin signaling in asthma.
View Article and Find Full Text PDF

The fault diagnosis on a transmission line based on the characteristics of the power spectral entropy is proposed in this article. The data preprocessing for the experimental measurement is also introduced using the EEMD. The EEMD is used to preprocess experimental measurements, which are nonlinear and non-stationary fault signals, to overcome the mode mixing.

View Article and Find Full Text PDF

Background: Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent platinum-based chemoradiotherapy.

Methods: In a phase 3, double-blind, randomized, placebo-controlled trial, we assigned patients to receive durvalumab at a dose of 1500 mg, durvalumab (1500 mg) plus tremelimumab at a dose of 75 mg (four doses only), or placebo every 4 weeks for up to 24 months. Randomization was stratified according to disease stage (I or II vs.

View Article and Find Full Text PDF

Background: Alleviating the sore throat caused by acute pharyngitis is a primary patient concern. However, antibiotics are not commonly recommended drugs, and abuse can lead to serious consequences such as drug resistance. Therefore, seeking alternative treatments is necessary.

View Article and Find Full Text PDF

Tumor-associated macrophages (TAMs) are important components of the tumor microenvironment (TME) and strongly associated with poor prognosis and drug resistance, including checkpoint blockade immunotherapy in solid tumor patients. However, the mechanism by which TAM affects immune metabolism reprogramming and immune checkpoint signalling pathway in the TME remains elusive. In this study we found that transforming growth factor-beta (TGF-β) secreted by M2-TAMs increased the level of glycolysis in bladder cancer (BLCA) and played important role in PD-L1-mediated immune evasion through pyruvate kinase isoenzymes M2 (PKM2).

View Article and Find Full Text PDF
Article Synopsis
  • The RESILIENT trial compared the effectiveness of liposomal irinotecan and topotecan as second-line treatments for small cell lung cancer (SCLC) after initial chemotherapy.
  • No significant difference in overall survival (OS) was observed, with liposomal irinotecan showing a median OS of 7.9 months and topotecan at 8.3 months.
  • Liposomal irinotecan had a higher objective response rate (ORR) of 44.1% compared to 21.6% for topotecan, but both treatments had similar safety profiles with grade ≥3 adverse events.
View Article and Find Full Text PDF

Background: Patients with cancer are at an increased risk of developing a hypercoagulative phenotype and venous thromboembolism. However, no clinical trial has yet confirmed that anticoagulant therapy improves cancer prognosis, and the mechanism underlying hypercoagulation in patients with bladder cancer is not well understood.

Objectives: We hypothesized that the prognostic genes affect tumor progression via tumor-mediated coagulation.

View Article and Find Full Text PDF
Article Synopsis
  • Chronic obstructive pulmonary disease (COPD) involves ongoing inflammation, mucus overproduction, and damage to lung tissue, and the Chinese herbal remedy Jianpiyifei II (JPYF II) shows promise in treating stable COPD.
  • The study aims to explore how JPYF II works against COPD, particularly its effects on the IL-17 pathway.
  • Researchers identified 88 bioactive components in JPYF II linked to 342 targets, with 284 targets potentially offering protective effects against COPD; crucial pathways and proteins were then analyzed to better understand JPYF II’s therapeutic mechanisms.
View Article and Find Full Text PDF

Objective: To evaluate the efficacy and safety of a hospital-made resuscitation pack, a Chinese medicinal herbal compound formula designed to enhance recovery in post-bronchoscopy patients.

Methods: In this randomized, single-blind, placebo-controlled clinical trial, eligible patients were randomly assigned 1:1 to either the treatment or control groups. The patients in the treatment group applied the resuscitation pack, which contained aromatic compounded Chinese herbs.

View Article and Find Full Text PDF
Article Synopsis
  • Cancer-associated fibroblasts (CAFs) significantly contribute to tumor growth and immune regulation in bladder cancer by remodeling the extracellular matrix and secreting various signaling molecules, yet their mechanisms remain poorly understood.
  • Analysis of gene expression and laboratory experiments revealed that the cytokine CXCL12, produced by CAFs, enhances bladder cancer cell migration and invasion while increasing the expression of the immune checkpoint protein PDL1 through the activation of the JAK2/STAT3 signaling pathway.
  • Blocking CXCL12 can suppress tumor growth, decrease PDL1 levels, and improve immune cell activity, suggesting that targeting CXCL12, alongside PDL1 inhibitors, may offer a promising approach to enhance immunotherapy strategies against bladder cancer.
View Article and Find Full Text PDF

ALDH1A1 is one of the classical stem cell markers for bladder cancer. Lysine 2-hydroxyisobutyrylation (Khib) is a newfound modification to modulate the protein expression, and the underlying mechanisms of how ALDH1A1 was regulated by Khib modification in bladder cancer remains unknown. Here, ALDH1A1 showed a decreased K260hib modification, as identified by protein modification omics in bladder cancer.

View Article and Find Full Text PDF

Purpose: In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB).

Experimental Design: Patients were randomized (1:1:1) to durvalumab (1,500 mg) plus EP, durvalumab plus tremelimumab (75 mg) plus EP, or EP alone.

View Article and Find Full Text PDF

Background: Postinfectious cough (PIC) is a common symptom following a respiratory tract infection. Xingbei Zhike (XBZK) granules, a Chinese patent medicine, has been widely used for PIC in clinics. However, there is a lack of evidence on the effectiveness.

View Article and Find Full Text PDF

Medical image segmentation is a crucial and intricate process in medical image processing and analysis. With the advancements in artificial intelligence, deep learning techniques have been widely used in recent years for medical image segmentation. One such technique is the U-Net framework based on the U-shaped convolutional neural networks (CNN) and its variants.

View Article and Find Full Text PDF

In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone. Ninety-two eligible patients were randomly assigned in a 3:1 ratio to receive the combination of ipilimumab and nivolumab, or ipilimumab alone. The primary endpoint was progression-free survival.

View Article and Find Full Text PDF

Cancer severely threatens human health, which makes it particularly urgent to develop effective strategies for cancer diagnosis and therapy. Gene therapy and nucleic acid-based cancer diagnosis play important roles in cancer theranostic, but their applicability is challenged by the low cellular uptake and enzymatic degradation. In response, safe and efficient carrier metal-organic frameworks (MOFs) have been proposed.

View Article and Find Full Text PDF

Second-line treatment options are limited for patients with small-cell lung cancer (SCLC). We conducted a PRISMA-standard systematic literature review to evaluate the treatment landscape for patients with relapsed SCLC (PROSPERO number: CRD42022299759). Systematic searches of MEDLINE, Embase, and Cochrane Library were performed (October 2022) to identify publications (prior 5 years) from prospective studies of therapies for relapsed SCLC.

View Article and Find Full Text PDF

Background: Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage III or IV melanoma is unknown.

Methods: In a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adjuvant pembrolizumab (neoadjuvant-adjuvant group) or to surgery followed by pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses) for approximately 1 year or until disease recurred or unacceptable toxic effects developed (adjuvant-only group). The primary end point was event-free survival in the intention-to-treat population.

View Article and Find Full Text PDF

Background: Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRAS mutation who had been previously treated with other anticancer drugs.

Methods: We conducted a randomised, open-label phase 3 trial at 148 centres in 22 countries.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC), which is among the most globally prevalent cancers, is strongly associated with liver cirrhosis. Using a bioinformatics approach, we have identified and investigated the hub genes responsible for the progression of cirrhosis into HCC. We analyzed the Gene Expression Omnibus (GEO) microarray datasets, GSE25097 and GSE17549, to identify differentially expressed genes (DEGs) in these two conditions and also performed protein-protein interaction (PPI) network analysis.

View Article and Find Full Text PDF

Background: Acupoint application of herbal medicine (AAHM) has been widely used in China. At present, there is no systematic review of AAHM versus placebo in the treatment of asthma. This systematic review aims to assess the efficacy of AAHM for asthma.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is one of the most important causes of cancer-related deaths and remains a major public health challenge worldwide. Considering the extensive heterogeneity of HCC, more accurate prognostic models are imperative. The circadian genes regulate the daily oscillations of key biological processes, such as nutrient metabolism in the liver.

View Article and Find Full Text PDF